X
AbbVie braces for impact of Humira biosimilars in Europe
https://pharmaphorum.com/news/abbvie-braces-for-impact-of-humira-biosimilars-in-europe/
AbbVie
Biogen gets go-ahead for EU Humira launch in October
But deal with Samsung prevents US launch until mid-2023
AbbVie to file long-acting psoriasis contender
AbbVie hopes risankizumab will rebuild sales after Humira patent expires
AbbVie signs $225m ‘immunoneurology’ deal to tackle Alzheimer’s
Partnership will use novel approach to treating Alzheimer’s.
Ready to pounce: Samsung joins Amgen with Humira biosimilar approval
No-one can launch biosimilars until patent expires next year
Janssen/AbbVie drug approved in graft-versus-host disease
First use for Imbruvica outside blood cancer.
UK court overturns AbbVie Humira patents
Decision paves way for cheaper competitor in autumn 2018.
NICE rejects AbbVie/Roche CLL drug Venclyxto
Body unconvinced by clinical data for Venclyxto .
